Bearbmagovva

Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model

Combination immunotherapy has emerged as a promising strategy to increase the immune response in glioblastoma (GBM) and overcome the complex immunosuppression occurring in its microenvironment. In this study, we hypothesized that combining DNA vaccines-to stimulate a specific immune response-and dua...

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkkit:	Mathilde Bausart (Dahkki), Kevin Vanvarenberg (Dahkki), Bernard Ucakar (Dahkki), Alessandra Lopes (Dahkki), Gaëlle Vandermeulen (Dahkki), Alessio Malfanti (Dahkki), Véronique Préat (Dahkki)
Materiálatiipa:	Girji
Almmustuhtton:	MDPI AG, 2022-05-01T00:00:00Z.
Fáttát:	article
Liŋkkat:	Connect to this object online.
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma
Dahkki: Alessio Malfanti, et al.
Almmustuhtton: (2022)

Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma
Dahkki: Alessandra Lopes, et al.
Almmustuhtton: (2017)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
Dahkki: Giulio Metro, et al.
Almmustuhtton: (2021)

Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer
Dahkki: Jiaojie Wei, et al.
Almmustuhtton: (2019)

Synergistic effect of doxorubicin lauroyl hydrazone derivative delivered by α-tocopherol succinate micelles for the treatment of glioblastoma
Dahkki: Mingchao Wang, et al.
Almmustuhtton: (2023)

Immune Checkpoint in Glioblastoma: Promising and Challenging
Dahkki: Jing Huang, et al.
Almmustuhtton: (2017)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
Dahkki: Melissa Sarver, et al.
Almmustuhtton: (2022)

Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway
Dahkki: David Hodson, et al.
Almmustuhtton: (2023)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
Dahkki: Sakeena Fatima, BA, et al.
Almmustuhtton: (2018)

Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology
Dahkki: Benjamin A Babalola, et al.
Almmustuhtton: (2021)

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
Almmustuhtton: (2019)

Immune checkpoint blockade therapy in head and neck cancer: a review
Dahkki: Shajedul Islam, et al.
Almmustuhtton: (2018)

Tumor lysis syndrome and collateral immune activation in dual checkpoint blockade
Dahkki: Risa Konishi, et al.
Almmustuhtton: (2021)

Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis
Dahkki: Yantao Xu, et al.
Almmustuhtton: (2022)

Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases
Dahkki: Sonja Braasch, et al.
Almmustuhtton: (2022)

27 HIV-associated gastrointestinal microbial dysbiosis influences the efficacy of anti-HIV immunity by immune checkpoint blockade
Dahkki: I.N. SahBandar, et al.
Almmustuhtton: (2017)

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan
Dahkki: Mitsunobu Otsuru, et al.
Almmustuhtton: (2024)

Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles
Dahkki: Yuxuan Liu, et al.
Almmustuhtton: (2024)

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients
Dahkki: Zhang J, et al.
Almmustuhtton: (2024)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
Dahkki: Damian J. Ralser, et al.
Almmustuhtton: (2023)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
Dahkki: Qiuyu Wu, et al.
Almmustuhtton: (2023)

Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
Dahkki: Ai Tsuji, et al.
Almmustuhtton: (2023)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
Dahkki: Li J, et al.
Almmustuhtton: (2023)

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
Dahkki: Jiulong Zhang, et al.
Almmustuhtton: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Dahkki: Tianrui Yang, et al.
Almmustuhtton: (2021)

Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
Dahkki: Jing Yu, et al.
Almmustuhtton: (2022)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
Dahkki: Zefan Liu, et al.
Almmustuhtton: (2023)

Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish
Dahkki: Xiaolin Ai, et al.
Almmustuhtton: (2022)

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects
Dahkki: James Brown, et al.
Almmustuhtton: (2022)

Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy
Dahkki: Yujeong Moon, et al.
Almmustuhtton: (2024)

Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer
Dahkki: Xing Bian, et al.
Almmustuhtton: (2023)

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
Dahkki: Lu Li, et al.
Almmustuhtton: (2022)

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
Dahkki: David M. Miller, MD, PhD, et al.
Almmustuhtton: (2017)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
Dahkki: Dan Zheng, et al.
Almmustuhtton: (2022)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
Dahkki: Yiting Sun, et al.
Almmustuhtton: (2021)

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
Dahkki: Yang Liu, et al.
Almmustuhtton: (2024)

Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer
Dahkki: Bohan Fan, et al.
Almmustuhtton: (2023)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
Dahkki: Renguo Guan, et al.
Almmustuhtton: (2022)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Almmustuhtton: (2023)

Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy
Dahkki: Ge Qin, et al.
Almmustuhtton: (2024)